Owkin launches ATLANTIS patient data mining project

Artificial intelligence specialist Owkin has added another piece to its medical research portfolio with the launch of ATLANTIS, a patient data mining programme, in partnership with 20 leading healthcare institutions.

ATLANTIS will harvest and analyse patient data from multiple sources – from electronic health records, medical imaging, physician notes, and diagnostic results, for example – which Owkin says will break down data silos and free up access to previously inaccessible data, accelerating medical research, the discovery of new medicines, and diagnostics.

The 20 healthcare institutions – from France, Spain, Germany, Italy, the US, the UK, and Israel – will map 11 therapeutic areas across oncology, immunology and inflammation, and neurology.

The findings will be used to power Owkin's operating software Owkin K, a suite of AI agents to decode complex biology, accelerate research, and automate processes to increase productivity in drug discovery and development.

Meanwhile, in return, the healthcare partners – which include the Royal Marsden NHS Foundation Trust and Newcastle Upon Tyne NHS Foundation Trust in the UK – will enhance their own AI capabilities and get insights into their data that can support their own research projects. The ATLANTIS project started in September and is due to be completed by May 2025.

"Owkin is committed to fostering collaboration between data scientists and patient data to achieve unparalleled insights and innovation," said Agathe Arlotti, head of partnerships at the French-American start-up.

"By combining our AI expertise with leading healthcare partners, we are creating a patient data network that pushes the boundaries of biomedical research," she added. "Together, we are fuelling breakthroughs for patients."

The 11 programmes include seven in oncology, spanning non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, and multiple myeloma (MM).

There are also three in immunology and inflammation – ulcerative colitis (UC), Crohn's disease (CD), and systemic lupus erythematosus (SLE) – as well as Alzheimer's disease (AD) in neurology.

Owkin affiliate company Epkin recently started the phase 1 INVOKE clinical trial of the first drug to be developed using Owkin K – a first-in-class EP2/EP4/DP1 triple inhibitor codenamed OKN4395 that has emerged from a collaboration with Idorsia – in patients with solid tumours.

In January, Owkin joined forces with generative AI (GenAI) specialist Absci to co-develop new biologics for targets in oncology and other diseases, including immunology and inflammation.